Fig. 2From: A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancerDistant recurrence in luminal breast cancer is not associated with strong modulation of immune infiltration. Boxplots showing total count of stained cells per mm2 for lymphocytes on HES sections (a), B lymphocytes using CD20 marker (b), CD8+ T lymphocytes (c), CD4+ T lymphocytes (e), FOXP3+ T lymphocytes (f), Th1 T lymphocytes using Tbet marker (g), Th17 T lymphocytes using IL17 marker (h), TLS count on HES sections (i), dendritic cells using DC Lamp marker (j), macrophages using CD163 marker (k), PD-L1+ immune cells (l), and PD-1+ lymphocytes (m) according to the recurrence status and the molecular subtype. N = 104 patients (52 controls and 52 cases) for all immune analyses except for PD-1 and PD-L1 markers (N = 44, 22 controls, 22 cases). d Representative views of CD4 + T lymphocytes immunostaining in either controls (left) and cases (right) (scale bar = 100 μm for larger views and 50 μm for inserts). p values are from Wilcoxon tests. The color code for boxplots is indicated at the top right of the figure. It depicts the BC subtype assessed by Prosigna™ test. Luminal A BC are in light blue (controls, N = 37) and light red (cases, N = 27). Luminal B BC are in dark blue (controls, N = 11) and dark red (cases, N = 19). HER2-enriched BC are in light green (controls, N = 2) and dark green (cases, N = 2). The basal-like BC is in yellow. BC without result for Prosigna™ test are represented in gray (2 controls and 3 cases)Back to article page